

Table S3. SNaPshot and sizing assay results for lung cancer cell lines. Among 35 samples, 23 (65.7%) mutations were found: *EGFR*: 8 (22.9%), *KRAS*: 8 (22.9%), *BRAF*: 1 (2.9%), *PIK3CA*: 2 (5.7%), *MEK1*: 1 (2.9%), *NRAS*: 2 (5.7%), *HER2*: 1 (2.9%). WT: wildtype. bps: basepairs. ins :insertion. del: deletion. *: these 19 samples were assessed independently by two different individuals in the laboratory, and 100% concordance was obtained.

Cell Lines	EGFR	KRAS	BRAF	NRAS	PIK3CA	MEK1	HER2	AKT1	PTEN
A549*	WT	G12S; 34G>A	WT	WT	WT	WT	WT	WT	WT
BFTC	WT	WT	WT	Q61L; 182A>T	WT	WT	WT	WT	WT
Calu 3*	WT	WT	WT	WT	WT	WT	WT	WT	WT
11-18*	L858R; 2573T>G	WT	WT	WT	WT	WT	WT	WT	WT
H1437*	WT	WT	WT	WT	WT	Q56P; 167A>C	WT	WT	WT
H157*	WT	G12R;34G>C	WT	WT	WT	WT	WT	WT	WT
H1648*	WT	WT	WT	WT	WT	WT	WT	WT	WT
H1650*	19 del (15bps)	WT	WT	WT	WT	WT	WT	WT	WT
H1666	WT	WT	G466V; 1397T>C	WT	WT	WT	WT	WT	WT
H1781*	WT	WT	WT	WT	WT	WT	20 ins(3bps)	WT	WT
H1819*	WT	WT	WT	WT	WT	WT	WT	WT	WT
H1975*	T790M; 2368C>T L858R; 2573T>G		WT	WT	WT	WT	WT	WT	WT
H1993*	WT	WT	WT	WT	WT	WT	WT	WT	WT
H2009*	WT	G12A; 35G>C	WT	WT	WT	WT	WT	WT	WT
H2030*	WT	G12C; 34G>T	WT	WT	WT	WT	WT	WT	WT
H23*	WT	G12C; 34G>T	WT	WT	WT	WT	WT	WT	WT
H2882*	WT	WT	WT	WT	WT	WT	WT	WT	WT
H3255*	L858R; 2573T>G	WT	WT	WT	WT	WT	WT	WT	WT
H358*	WT	G12C; 34G>T	WT	WT	WT	WT	WT	WT	WT
H460	WT	Q61H; 183A>T	WT	WT	E545K; 1633G>A	WT	WT	WT	WT
H522*	WT	WT	WT	WT	WT	WT	WT	WT	WT
H820*	T790M; 2368C>T, 19 del (12 bps)	WT	WT	WT	WT	WT	WT	WT	WT

Formatted: French (France)

Cell Lines	EGFR	KRAS	BRAF	NRAS	PIK3CA	MEK1	HER2	AKT1	PTEN
PC-9	19 del (15bps)	WT	WT	WT	WT	WT	WT	WT	WT
H226	WT	WT	WT	WT	WT	WT	WT	WT	WT
HCC95	WT	WT	WT	WT	WT	WT	WT	WT	WT
H520	WT	WT	WT	WT	WT	WT	WT	WT	WT
SKMES-1	WT	WT	WT	WT	WT	WT	WT	WT	WT
SW900	WT	G12V; c.35G>T	WT	WT	WT	WT	WT	WT	WT
H69	WT	WT	WT	WT	WT	WT	WT	WT	WT
H82	WT	WT	WT	WT	WT	WT	WT	WT	WT
H146	WT	WT	WT	WT	WT	WT	WT	WT	WT
H209	WT	WT	WT	WT	WT	WT	WT	WT	WT
H1618	WT	WT	WT	WT	WT	WT	WT	WT	WT
Detroit562	WT	WT	WT	WT	H1047R; 3140A>G	WT	WT	WT	WT
HCC15	WT	WT	WT	Q61K; 181C>A	WT	WT	WT	WT	WT